Taking Ozempic? The findings every woman should know

A preliminary study in Australia found that semaglutide, the active ingredient in Ozempic and Wegovy, reduced blood flow to the uterus and oxygen levels in the fetus of pregnant sheep. The researchers emphasize that the findings are not in humans and call for further research.

A new study from the University of Adelaide in Australia found that the active ingredient in the weight-loss drugs Ozempic and Wegovy, semaglutide, may reduce blood flow to the uterus and oxygen levels in the fetus in animals. The study, published in the journal Heart, Lung and Circulation, was conducted on pregnant sheep using advanced MRI technology. Within two hours of drug administration, there was a significant decrease in blood flow to the uterus. The researchers, including Dr. Mitchell Lock and Prof. Janna Morrison, emphasize that these are preliminary findings not yet proven in humans, but call for further research. The current official recommendation is to stop treatment with these drugs before becoming pregnant.

Taking Ozempic? The findings every woman should know